As a small, privately held biotech, the Australian venture Implicit Bioscience believes its business model has a number of advantages, low risk being chief among them.

Anti-angiogenesis as a treatment for cancer was hardly a new concept, even in 1998 when a New York Times article first put Judah Folkman's work on the public map. Although the hype has died away, the industrial machine of anti-angiogenesis has continued to roll on--as indicated by the start-up activity we describe in the following profiles.